Industry News - Ionis announced positive topline results for its antisense oligonucleotide therapy Tryngolza (Olezarsen) in the Phase 3 Essence clinical trial, significantly reducing triglyceride levels in patients after 6 months and achieving all key secondary endpoints with statistical significance [2] Company News - Health元 announced that its subsidiary LIAN SGP plans to acquire 64.81% of Vietnamese listed company Imexpharm for approximately 15.87 million RMB, which is a leading pharmaceutical company in Vietnam with products that include antibiotics and cardiovascular drugs, showing high synergy with Health元's existing products [3] - 众生药业 reported that its subsidiary 众生睿创's innovative drug Angladiwe tablets received approval from the National Medical Products Administration, being the first global RNA polymerase PB2 protein inhibitor for treating adult patients with uncomplicated influenza A [3] - 科伦药业 announced that its subsidiary 科伦博泰's new indication application for the ADC drug sac-TMT has been accepted by CDE, aimed at treating adults with HR+ and HER2- breast cancer who have previously received endocrine therapy and other systemic treatments [3] - 艾力斯 announced that its KRASG12C inhibitor, citric acid gorasetinib tablets, has received approval from the National Medical Products Administration for treating adult patients with advanced non-small cell lung cancer with KRASG12C mutations who have received at least one systemic treatment [4]

Group 1 - The recombinant protein concept sector rose by 2.52%, ranking second among concept sectors, with 30 stocks increasing in value [1][2] - Notable gainers included Sangon Biotech, which hit the daily limit with a 20% increase, and other significant performers such as Sai Sheng Pharmaceutical, Jie Ya Co., and Jinbo Bio, which rose by 16.37%, 9.31%, and 9.17% respectively [1][2] - The sector experienced a net inflow of 221 million yuan from main funds, with 23 stocks receiving net inflows, and 8 stocks exceeding 10 million yuan in net inflow [2][3] Group 2 - Leading the net inflow was Xilong Scientific, which saw a net inflow of 242 million yuan, followed by Rejuve Pharmaceutical and Zexin Pharmaceutical with net inflows of 37.78 million yuan and 32.48 million yuan respectively [2][3] - The top three stocks by net inflow ratio were Xilong Scientific at 20.85%, Zexin Pharmaceutical at 8.53%, and Chengdu Xian Dao at 7.96% [3][4] - Stocks with notable declines included Furuida, Zhongyuan Xiehe, and Wanmei Biological, which fell by 2.25%, 1.92%, and 1.80% respectively [1][5]

Market Performance - Major stock indices in China saw significant gains, with the North China 50 Index rising over 1% to reach a new high [1] - The FTSE China A50 Index futures increased by more than 1%, while the offshore RMB appreciated by 101 points against the USD, currently at 7.2041 [2] - The Shanghai Composite Index closed up 0.38% at 3393.49 points, with the Shenzhen Component Index up 0.53% and the ChiNext Index up 0.99% [2] Sector Highlights - The coal sector showed strong performance, with companies like Dayou Energy and Jinkong Coal Industry hitting the daily limit, and Shanmei International rising nearly 6% [2] - The solid-state battery concept gained traction, with companies like Lingpai Technology and Ningde Times seeing significant price increases, with Lingpai Technology hitting a 20% limit up [2][4] - The innovative drug sector remained active, with Shuyitai and SanSheng Guojian both hitting the daily limit, and SaiSheng Pharmaceutical rising over 12% [7] Company Developments - Ningde Times, which recently listed on the Hong Kong Stock Exchange, saw its stock rise by over 9% during trading [3] - Bubble Mart reached a new historical high, with its stock price rising over 5% to 220 HKD per share, bringing its market capitalization close to 300 billion HKD [10] - Bubble Mart's Labubu 3.0 product has gained immense popularity globally, leading to long queues in stores and significant price premiums on secondary markets [12] Industry Trends - The solid-state battery sector is identified as a core focus within the lithium battery industry, with companies actively launching new products and materials seeing increased demand [6] - The innovative drug market in China is projected to grow from 132.5 billion USD in 2019 to 159.2 billion USD by 2024, maintaining a global market share of around 15% [9]

Core Viewpoint - The innovative pharmaceutical sector experienced a significant surge, with multiple companies achieving substantial stock price increases, indicating a positive market sentiment towards domestic innovative drugs and their international expansion opportunities [1][2]. Group 1: Market Performance - On May 21, the innovative drug sector saw a broad increase, with companies like Sanofi Guojian and Shuyou Shen reaching their daily price limits, while others like Saiseng Pharmaceutical and Ruizhi Pharmaceutical rose over 10% [1]. - Specific stock performances included Sanofi Guojian (688336.SS) achieving a price of 47.24 with a 19.99% increase, and Shuyou Shen (300204.SZ) reaching 14.15 with a 20.02% increase [2]. Group 2: International Expansion of Domestic Innovative Drugs - On May 19, Sanofi Guojian and its affiliates granted Pfizer exclusive rights for the development, production, and commercialization of a product, with an upfront payment of $12.5 billion and potential milestone payments up to $4.8 billion [3]. - On May 15, Shiyao Group announced an exclusive licensing agreement with Cipla for the commercialization of a drug in the U.S., with an upfront payment of $15 million and potential total payments nearing $1.1 billion [3]. - Data from Yao Medicine Cube indicated that in 2024, China completed 94 transactions for innovative drug licensing abroad, totaling $51.9 billion, a 26% year-on-year increase [3]. Group 3: Institutional Insights - Following a recent executive order by former U.S. President Trump aimed at lowering drug prices, the impact on China's innovative drug exports is expected to be minimal [4]. - The domestic innovative drug policy is anticipated to undergo significant changes, with 2025 expected to be a pivotal year for policy implementation, including the introduction of a new insurance directory and support for innovative drug pricing mechanisms [5]. - Projections indicate that the net profit for A/H innovative drug companies in 2024 will reach 11.67 billion, a substantial increase from 670 million in 2023, reflecting improved industry profitability [5].

智通财经5月21日电，舒泰神20CM涨停，此前三生国健3连板，赛升药业、海创药业、海辰药业、诺思 格、君实生物等跟涨。消息面上，港股创新药企三生制药公告称，其与辉瑞公司就前者自主研发的PD- 1/VEGF双特异性抗体SSGJ-707签订了独家许可协议。本次协议中12.5亿美元的首付款再次刷新了国产 创新药出海首付款金额纪录。 创新药概念延续强势 舒泰神20CM涨停 ...

Industry Overview - The recombinant protein sector has shown active performance, with a nearly 4% increase in the market as of May 20, highlighted by stocks such as Yipinhong (300723) and Weiming Pharmaceutical (002581) reaching their daily limit [1] - Recombinant proteins are produced using recombinant DNA or RNA technology, allowing host cells to express proteins that are either identical to or modified versions of natural proteins, enhancing properties like solubility or yield [1] - Key applications of recombinant proteins include biopharmaceuticals, cell immunotherapy, and diagnostic reagent development, playing a crucial role in vaccine production, monoclonal antibodies, and innovative drugs for cancer treatment, autoimmune diseases, and rare diseases [1] Market Growth - The global recombinant protein market grew from $7 billion in 2015 to $10.8 billion in 2020, with a compound annual growth rate (CAGR) of 9.0%, and is projected to reach $20.8 billion by 2025, with a CAGR of approximately 14.1% from 2020 to 2025 [2] - Historically, the global recombinant protein market has been dominated by international brands, but domestic companies are increasingly investing in R&D to enhance their technology and product quality, leading to a significant trend of import substitution [2] Company Highlights - Yipinhong has established a recombinant protein R&D and pilot production facility, enabling capabilities in biopharmaceutical development [3] - Weiming Pharmaceutical's subsidiary, Shandong Yandu, has developed a high-expression recombinant protein platform, creating multiple biopharmaceutical R&D systems [3] - Sangfor Biopharma focuses on innovative therapeutic antibody drugs, specializing in monoclonal antibodies, bispecific antibodies, and multifunctional recombinant proteins [3] - Kexing Pharmaceutical is a leading company in China's recombinant protein drug sector, with a comprehensive biopharmaceutical R&D innovation system [4] - Furuida has been deeply involved in the recombinant collagen field, utilizing synthetic biology techniques to select high-bioactive segments from human type III collagen [4] - Saiseng Pharmaceutical has formed a technical system centered on proteomics, antibody platforms, drug R&D, and fine recombinant protein production [4] - Jieya Co., Ltd. has partnered with Chuangjian Medical to establish Anhui Jiechuang Medical Equipment Co., Ltd., focusing on recombinant collagen protein business [4] - Shenzhou Cell has developed a high-efficiency, high-throughput technology platform covering the entire biopharmaceutical R&D and production chain, with a diverse pipeline of monoclonal antibodies, recombinant proteins, and vaccines [4]

Market Performance - The recombinant protein sector declined by 1.56%, ranking among the top losers in concept sectors as of April 25 [1][2] - Notable stocks within the sector that hit the daily limit down include Jiangsu Wuzhong and Weiming Pharmaceutical, while stocks like HJ Bio, Wanfang Development, and Aladdin saw significant declines [1] Top Gainers and Losers - Among the top gainers in the recombinant protein sector, Borui Pharmaceutical, BeiDa Pharmaceutical, and Tonghua Dongbao increased by 4.39%, 2.42%, and 2.31% respectively [1] - The sector experienced a net outflow of 158 million yuan, with 22 stocks seeing net outflows, and five stocks exceeding 10 million yuan in outflows [2] Capital Flow Analysis - The stock with the highest net outflow was Xilong Science, with a net outflow of 190 million yuan, followed by Furida and Dezhan Health with outflows of 19.41 million yuan and 19.18 million yuan respectively [2][3] - Conversely, the stocks with the highest net inflows included Zhongyuan Qihua, Zhifei Biological, and Chengdu Xian Dao, with inflows of 26.63 million yuan, 25.06 million yuan, and 17.51 million yuan respectively [2][3]

Financial Performance - The company reported a basic earnings per share of 0.0830 yuan for Q1 2025, a significant increase of 120.98% compared to a loss of 0.3957 yuan in Q1 2024 [1] - Net profit for Q1 2025 was 0.4 billion yuan, recovering from a loss of 1.91 billion yuan in Q1 2024, marking a 120.94% increase [1] - Operating revenue decreased to 0.93 billion yuan in Q1 2025, down 15.45% from 1.1 billion yuan in Q1 2024 [1] - The return on equity (ROE) improved to 1.18% in Q1 2025 from -5.71% in Q1 2024 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 77.25 million shares, accounting for 28.22% of the circulating shares, with a decrease of 1.8142 million shares compared to the previous period [1] - Major shareholders include Ma Qiao with 59.62 million shares (21.77%), and Ma Li with 7.46 million shares (2.73%), both remaining unchanged [2] - New entrants among the top shareholders include Goldman Sachs and Morgan Stanley, while several previous shareholders have exited the top ten list [2] Dividend Policy - The company has announced that it will not distribute dividends or transfer shares this time [3]

投资者关系活动记录表 证券代码：300485 证券简称：赛升药业 北京赛升药业股份有限公司 投资者关系活动记录表 编号：2025-001 投资者关系活动 类别 □特定对象调研 □ 分析师会议 □ 媒体采访 √ 业绩说明会 □ 新闻发布会 □ 路演活动 □ 现场参观 □ 其他 （请文字说明其他活动内容） 参与单位名称及 人员姓名 线上参与本公司 2024 年度网上业绩说明会的投资者 时间 2025 年 4 月 17 日（周四）下午 15:00-16:30 地点 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） 采用网络远程的方式召开业绩说明会 上市公司接待人 员姓名 董事长兼总经理 马骉 董秘 王雪峰 财务总监 梁东娜 独立董事 刘锋 投资者关系活动 主要内容介绍 公司于 2025 年 04 月 17 日（星期四）15:00-16:30 采用网络远 程方式召开 2024 年度业绩网上说明会，就 2024 年度经营情况与 投资者进行互动交流，主要内容如下： 1、【查询-003】高管您好，能否请您介绍一下本期行业整体和 行业内其他主要企业的业绩表现？ 谢谢。 答：2024 年度整体行业年 ...

监事会2023年度工作报告 2023年，北京赛升药业股份有限公司（以下简称"公司"）监事会严格按照 《中华人民共和国公司法》《中华人民共和国证券法》《上市公司信息披露管理 办法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律 监管指引第2号——创业板上市公司规范运作》《上市公司监事会工作指引》以 及《公司章程》《监事会议事规则》等法律法规、规范性文件及监管部门的相关 规定和要求，全体监事恪尽职守、勤勉尽责、认真履行监督职责，对董事会和 高级管理层及其成员履职、财务活动、内部控制、风险管理进行了监督，参与公 司重大决策、决定的研究，并列席了本年度召开的公司董事会及股东大会，确保 公司规范、有序的运作。现就公司监事会2023年度主要工作情况报告如下： 北京赛升药业股份有限公司 2、检查公司财务情况 一、监事会运行情况 2023年，监事会共召开会议6次，审议通过22项议案，会议的通知、召开和 表决程序符合相关规定。具体情况如下： | 序号 | 会议届次 | | | 召开日期 | | | 会议决议 | | --- | --- | --- | --- | --- | --- | --- | --- | ...